CerRx is a Texas-based oncology drug development startup company focused on the development of novel anticancer therapies that target the biochemical pathways of certain toxic waxes in cancer cells, called “ceramides.” This ceramides-based technology effectively induces high rates of cancer cell death by increasing and manipulating toxic ‘ceramides' exclusively in cancer cells. Because ceramide levels are not increased in healthy normal cells, the CerRx agents allow the opportunity for broad use in many different tumor types with a high safety profile – the experience already seen to date in early clinical trials.
CerRx has multiple clinical trials in progress including their first pivotal registration trial in an aggressive form of lymphoma call peripheral T-cell lymphoma (PTCL). A second trial targeting another difficult to treat lymphoma called cutaneous T-cell lymphoma (CTCL) will be starting in 2019. Both of these trials have received financial support through the Cancer Prevention and Research Institute of Texas (CPRIT).